Role of Oxidative Stress in Peyronie’s Disease: Biochemical Evidence and Experiences of Treatment with Antioxidants
Open accessThe DOI matches its Crossref record; 188 of the 193 references it cites were found in a registry or an index.
Abstract
Background: Peyronie’s disease (PD) is a chronic inflammatory condition affecting adult males, involving the tunica albuginea of the corpora cavernosa of the penis. PD is frequently associated with penile pain, erectile dysfunction, and a secondary anxious–depressive state. The etiology of PD has not yet been completely elucidated, but local injury is generally recognized to be a triggering factor. It has also been widely proven that oxidative stress is an essential, decisive component in all inflammatory processes, whether acute or chronic. Current conservative medical treatment comprises oral substances, penile injections, and physical therapy. Aim: This article intends to show how antioxidant therapy is able to interfere with the pathogenetic mechanisms of the disease. Method: This article consists of a synthetic narrative review of the current scientific literature on antioxidant therapy for this disease. Results: The good results of the antioxidant treatment described above also prove that the doses used were adequate and the concentrations of the substances employed did not exceed the threshold at which they might have interacted negatively with the mechanisms of the redox regulation of tissue. Conclusions: We believe new, randomized, controlled studies are needed to confirm the efficacy of treatment with antioxidants. However, we consider the experiences of antioxidant treatment which can already be found in the literature useful for the clinical practice of urologists in the treatment of this chronic inflammatory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The fibrotic changes may impede the expansion of the corpora cavernosa, the 2 cylindrical erectile tissues in the penis responsible for trapping blood during an erection.116”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [116]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“PD progresses in two main stages. The first phase typically lasts between 12 and 18 months; this phase is the “active inflammatory phase”, in which plaque forms and progresses to fibrosis and potential calcification, accompanied by pain and worsening of the penile deformity. In the second phase, known as the chronic “stabilized phase”, penile pain decreases and the plaque size and deformity stabil”
From Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases (2024) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“In the scientific literature, several articles have appeared in the 21st century that have clarified the important role that “oxidative stress” plays in the pathophysiology of PD [15,16,17,18,19,20,21,22].”
From Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases (2024) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Reactive Oxygen Species in Inflammation and Tissue Injury
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P., & Malik, A. B. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5149 · Cited by 4,897 · cited 1×
“It is therefore clear that a strong state of oxidation (oxidative and nitro-oxidative stress) created by the plentiful, prolonged local production of ROS and RNS, is a decisive factor for the progression and chronicization of inflammation [60,61].”
BackgroundThe complexity of NF-κB signaling in inflammation and cancer
Hoesel, B., & Schmid, J. A. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-86 · Cited by 3,165
Role of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
Health effects of quercetin: From antioxidant to nutraceutical
Boots, A. W., Haenen, G. R. M. M., & Bast, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.008 · Cited by 2,121
Oxidative Stress and Inflammation: What Polyphenols Can Do for Us?
Hussain, T., Tan, B., Yin, Y., Blachier, F., Tossou, M. C. B., & Rahu, N. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7432797 · Cited by 2,082
Role of ROS and RNS Sources in Physiological and Pathological Conditions
Di Meo, S., Reed, T. T., Venditti, P., & Victor, V. M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1245049 · Cited by 1,614
Lingappan, K. (2018) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.11.002 · Cited by 1,051
The interactions between inflammation and coagulation
Esmon, C. T. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05753.x · Cited by 1,003
Antioxidant and antiradical activities of l-carnitine
Gülçin, İ. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.05.103 · Cited by 993
Reactive Oxygen Species: Drivers of Physiological and Pathological Processes
Checa, J., & Aran, J. M. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s275595 · Cited by 984 · cited 1×
“It is therefore clear that a strong state of oxidation (oxidative and nitro-oxidative stress) created by the plentiful, prolonged local production of ROS and RNS, is a decisive factor for the progression and chronicization of inflammation [60,61].”
BackgroundTherapeutic potentials of superoxide dismutase.
Younus, H. (2018) · PubMed Central · Cited by 787
Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis
Liu, R.-M., & Desai, L. P. (2015) · Redox Biology · doi:10.1016/j.redox.2015.09.009 · Cited by 702
The antioxidant role of vitamin C
Bendich, A., Machlin, L. J., Scandurra, O., Burton, G. W., & Wayner, D. D. M. (1986) · Advances in Free Radical Biology & Medicine · doi:10.1016/s8755-9668(86)80021-7 · Cited by 684
Halliwell, B. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02075-4 · Cited by 655
Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations.
Frei, B., Kim, M. C., & Ames, B. N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4879 · Cited by 620
Lambert, E., Dassé, E., Haye, B., & Petitfrère, E. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.008 · Cited by 541
Cesari, M., Pahor, M., & Incalzi, R. A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00171.x · Cited by 448
Raso, G. M., Meli, R., Di Carlo, G., Pacilio, M., & Di Carlo, R. (2001) · Life Sciences · doi:10.1016/s0024-3205(00)00999-1 · Cited by 448
The prevalence of Peyronie's disease: results of a large survey
Schwarzer, U., Sommer, F., Klotz, T., Braun, M., Reifenrath, B., & Engelmann, U. (2001) · BJU International · doi:10.1046/j.1464-4096.2001.02436.x · Cited by 440
Biological activity of bee propolis in health and disease.
Lotfy, M. (2006) · PubMed · Cited by 437
Regulation of iNOS on Immune Cells and Its Role in Diseases
Xue, Q., Yan, Y., Zhang, R., & Xiong, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123805 · Cited by 421 · cited 1×
“The sources of production of the iNOS enzyme are macrophages, monocytes, T cells, smooth muscle cells, fibroblasts and myofibroblasts [43,45,57].”
BackgroundPeyronie’s Disease: AUA Guideline
Nehra, A., Alterowitz, R., Culkin, D. J., Faraday, M. M., Hakim, L. S., Heidelbaugh, J. J., Khera, M., Kirkby, E., McVary, K. T., Miner, M. M., et al. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.05.098 · Cited by 416
Proposal: Trauma as the Cause of the Peyronie's Lesion
Devine, C. J. J., Somers, K. D., Jordan, G. H., & Schlossberg, S. M. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65361-8 · Cited by 381
Modification of platelet function and arachidonic acid metabolism by bioflavonoids
Landolfi, R., Mower, R. L., & Steiner, M. (1984) · Biochemical Pharmacology · doi:10.1016/0006-2952(84)90423-4 · Cited by 341
Min, Y.-D., Choi, C.-H., Bark, H., Son, H.-Y., Park, H.-H., Lee, S., Park, J.-W., Park, E.-K., Shin, H.-I., & Kim, S.-H. (2007) · Inflammation Research · doi:10.1007/s00011-007-6172-9 · Cited by 330
Takada, Y., Bhardwaj, A., Potdar, P., & Aggarwal, B. B. (2004) · Oncogene · doi:10.1038/sj.onc.1208169 · Cited by 310
EAU guidelines on penile curvature
Hatzimouratidis, K., Eardley, I., Giuliano, F., Hatzichristou, D., Moncada, I., Salonia, A., Vardi, Y., & Wespes, E. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.040 · Cited by 309
Blotnick, S., Peoples, G. E., Freeman, M. R., Eberlein, T. J., & Klagsbrun, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2890 · Cited by 303
REGENERATION OF VITAMIN E FROM α-CHROMANOXYL RADICAL BY GLUTATHIONE AND VITAMIN C
Niki, E., Tsuchiya, J., Tanimura, R., & Kamiya, Y. (1982) · Chemistry Letters · doi:10.1246/cl.1982.789 · Cited by 284
Sasaki, K., Hattori, T., Fujisawa, T., Takahashi, K., Inoue, H., & Takigawa, M. (1998) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a021955 · Cited by 272 · cited 2×
“The production of iNOS is also stimulated by the cytokines IL-1 and TNF-alpha [58].”
BackgroundZhang, Y., McCluskey, K., Fujii, K., & Wahl, L. M. (1998) · PubMed · Cited by 268
Unleashing endogenous TNF-alpha as a cancer immunotherapeutic
Josephs, S. F., Ichim, T. E., Prince, S. M., Kesari, S., Marincola, F. M., Escobedo, A. R., & Jafri, A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1611-7 · Cited by 257
The Chronology of Depression and Distress in Men with Peyronie's Disease
Nelson, C. J., Diblasio, C., Kendirci, M., Hellstrom, W., Guhring, P., & Mulhall, J. P. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00895.x · Cited by 255 · cited 1×
“In PD patients, a depressive state is present in 48% of cases; it has also been found that psychological disorders can persist even after the successful treatment of PD [14,16].”
BackgroundModulation of the activity of pro-inflammatory enzymes, COX-2 and iNOS, by chrysin derivatives
Cho, H. (2004) · Pharmacological Research · doi:10.1016/s1043-6618(03)00248-2 · Cited by 246
Zhang, Y., McCluskey, K., Fujii, K., & Wahl, L. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.3071 · Cited by 245
Hou, D.-X., Yanagita, T., Uto, T., Masuzaki, S., & Fujii, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.05.003 · Cited by 231
α-Tocopherol Inhibits the Respiratory Burst in Human Monocytes
Cachia, O., Benna, J. E., Pedruzzi, E., Descomps, B., Gougerot-Pocidalo, M.-A., & Leger, C.-L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32801 · Cited by 230
Evidence-Based Management Guidelines on Peyronie's Disease
Chung, E., Ralph, D., Kagioglu, A., Garaffa, G., Shamsodini, A., Bivalacqua, T., Glina, S., Hakim, L., Sadeghi-Nejad, H., & Broderick, G. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.04.062 · Cited by 227
DiBenedetti, D. B., Nguyen, D., Zografos, L., Ziemiecki, R., & Zhou, X. (2011) · Advances in Urology · doi:10.1155/2011/282503 · Cited by 226
Role of Oxidative Stress in the Pathophysiological Mechanism of Erectile Dysfunction
Agarwal, A., Nandipati, K. C., Sharma, R. K., Zippe, C. D., & Raina, R. (2006) · Journal of Andrology · doi:10.2164/jandrol.05136 · Cited by 225 · cited 2×
“The iNOS enzyme is therefore locally produced in excess (100 to 1000 times more concentrated than normal constitutive NOS), leading to a chemical reaction and the production of high concentrations of nitric oxide radical (NO•-); i-NOS also bolsters the local synthesis of collagen [43,59].”
BackgroundValente, E. G. A., Vernet, D., Ferrini, M. G., Qian, A., Rajfer, J., & Gonzalez-Cadavid, N. F. (2003) · Nitric Oxide · doi:10.1016/j.niox.2003.12.002 · Cited by 223 · cited 1×
“In other studies, a number of antioxidants (vitamin B3, propionyl-L-carnitine, L-arginine) were used in association with other substances (verapamil, tadalafil) or penile traction [46,99,100].”
MethodGHOLAMI, S. S., GONZALEZ-CADAVID, N. F., LIN, C.-S., RAJFER, J., & LUE, T. F. (2003) · Journal of Urology · doi:10.1097/01.ju.0000053800.62741.fe · Cited by 211
PENILE TRAUMA: AN ETIOLOGIC FACTOR IN PEYRONIE'S DISEASE AND ERECTILE DYSFUNCTION
Jarow, J. P., & Lowe, F. C. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64222-8 · Cited by 202
Ginkgo biloba: A Treasure of Functional Phytochemicals with Multimedicinal Applications
Noor-E-Tabassum, Das, R., Lami, M. S., Chakraborty, A. J., Mitra, S., Tallei, T. E., Idroes, R., Mohamed, A. A.-R., Hossain, M. J., Dhama, K., et al. (2022) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2022/8288818 · Cited by 197
Ellulu, M. S., Rahmat, A., Ismail, P., Khaza'ai, H., & Abed, Y. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s83144 · Cited by 195
Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases
Jiang, Q., Yin, X., Lill, M. A., Danielson, M. L., Freiser, H., & Huang, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810962106 · Cited by 185
Alternative Pathways of IL-1 Activation, and Its Role in Health and Disease
Pyrillou, K., Burzynski, L. C., & Clarke, M. C. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613170 · Cited by 185
The effects of the molecular weights of hyaluronic acid on the immune responses
Lee, B. M., Park, S. J., Noh, I., & Kim, C.-H. (2021) · Biomaterials Research · doi:10.1186/s40824-021-00228-4 · Cited by 176
Mechanistic Insights into the Pharmacological Significance of Silymarin
Wadhwa, K., Pahwa, R., Kumar, M., Kumar, S., Sharma, P. C., Singh, G., Verma, R., Mittal, V., Singh, I., Kaushik, D., et al. (2022) · Molecules · doi:10.3390/molecules27165327 · Cited by 170
Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie's disease
Gonzalez-Cadavid, N. F., & Rajfer, J. (2005) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0201 · Cited by 168
Antifibrotic Role of Inducible Nitric Oxide Synthase
Ferrini, M. G., Vernet, D., Magee, T. R., Shahed, A., Qian, A., Rajfer, J., & Gonzalez-Cadavid, N. F. (2002) · Nitric Oxide · doi:10.1006/niox.2001.0421 · Cited by 167
Peyronie’s Disease: Prevalence and Association with Cigarette Smoking
La Pera, G., Pescatori, E. S., Calabrese, M., Boffini, A., Colombo, F., Andriani, E., Natali, A., Vaggi, L., Catuogno, C., Giustini, M., et al. (2001) · European Urology · doi:10.1159/000049830 · Cited by 165
Beneficial Effects of Hyaluronic Acid
Sudha, P. N., & Rose, M. H. (2014) · Advances in Food and Nutrition Research · doi:10.1016/b978-0-12-800269-8.00009-9 · Cited by 162
Rahman, M., Ichiyanagi, T., Komiyama, T., Hatano, Y., & Konishi, T. (2006) · Free Radical Research · doi:10.1080/10715760600815322 · Cited by 159
van't Hof, R. J., Armour, K. J., Smith, L. M., Armour, K. E., Wei, X. Q., Liew, F. Y., & Ralston, S. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130511497 · Cited by 158
Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem
Zozina, V. I., Covantev, S., Goroshko, O. A., Krasnykh, L. M., & Kukes, V. G. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666180416115428 · Cited by 158
Mast, B. A., Diegelmann, R. F., Krummel, T. M., & Cohen, I. K. (1993) · Matrix · doi:10.1016/s0934-8832(11)80110-1 · Cited by 154
Oxidative Stress, Plasminogen Activator Inhibitor 1, and Lung Fibrosis
Liu, R.-M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1903 · Cited by 150
Surgical Treatment of Peyronie’s Disease: A Critical Analysis
Kadıoğlu, A., Akman, T., Şanlı, Ö., Gürkan, L., Çakan, M., & Çeltik, M. (2006) · European Urology · doi:10.1016/j.eururo.2006.04.030 · Cited by 149
Acetyl‐ l ‐carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report
Biagiotti, G., & Cavallini, G. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02241.x · Cited by 142 · cited 1×
“Subsequently, in the early 2000s, carnitine was used to treat PD, specifically for its antioxidant properties, both alone (orally) and together with penile injections of a calcium channel blocker (Verapamil) [94,95].”
BackgroundThe Prevalence of Peyronie's Disease in the United States: A Population-Based Study
Stuntz, M., Perlaky, A., des Vignes, F., Kyriakides, T., & Glass, D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150157 · Cited by 137
Standard Operating Procedures for Peyronie's Disease
Levine, L. A., & Burnett, A. L. (2013) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.03003.x · Cited by 134
Martínez-Salamanca, J. I., Egui, A., Moncada, I., Minaya, J., Ballesteros, C. M., del Portillo, L., Sola, I., & Carballido, J. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12400 · Cited by 129
Potential Therapeutic Effect of Antioxidant Therapy in Shock and Inflammation
Cuzzocrea, S., Thiemermann, C., & Salvemini, D. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043365396 · Cited by 129
TNF-α inactivation of collagen receptors: implications for fibroblast function and fibrosis
Chou, D. H., Lee, W., & McCulloch, C. A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.11.4354 · Cited by 125
Combination of Penile Traction, Intralesional Verapamil, and Oral Therapies for Peyronie’s Disease
Abern, M. R., Larsen, S., & Levine, L. A. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02519.x · Cited by 121 · cited 1×
“In other studies, a number of antioxidants (vitamin B3, propionyl-L-carnitine, L-arginine) were used in association with other substances (verapamil, tadalafil) or penile traction [46,99,100].”
MethodVozenin, M., Sivan, V., Gault, N., Renard, C., Geffrotin, C., Delanian, S. E., Jl, L., & Martin, M. T. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00431-7 · Cited by 114
Reduced Thrombus Formation by Hyaluronic Acid Coating of Endovascular Devices
Verheye, S., Markou, C. P., Salame, M. Y., Wan, B., King, S. B., Robinson, K. A., Chronos, N. A. F., & Hanson, S. R. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.4.1168 · Cited by 112
The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease
Raheem, A. A., Garaffa, G., Raheem, T. A., Dixon, M., Kayes, A., Christopher, N., & Ralph, D. (2010) · BJU International · doi:10.1111/j.1464-410x.2010.09365.x · Cited by 108
Prevalence of Peyronie's disease in men over 50-y-old from Southern Brazil
Rhoden, E., Telöken, C., Ting, H., Lucas, M., Ros, C. T. D., & Souto, C. (2001) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900727 · Cited by 107
Antioxidant and Anti-Inflammatory Effects of Coenzyme Q10 Supplementation on Infectious Diseases
Sifuentes-Franco, S., Sánchez-Macías, D. C., Carrillo-Ibarra, S., Rivera-Valdes, J. J., Zúñiga, L. Y., & Sánchez-López, V. A. (2022) · Healthcare · doi:10.3390/healthcare10030487 · Cited by 107
A Critical Analysis of Nonsurgical Treatment of Peyronie’s Disease
Hauck, E. W., Thorsten Diemer, A., Schmelz, H. U., & Weidner, W. (2006) · European Urology · doi:10.1016/j.eururo.2006.02.059 · Cited by 105
Edwards, D. R., Leco, K. J., Beaudry, P. P., Atadja, P. W., Veillette, C., & Riabowol, K. T. (1996) · Experimental Gerontology · doi:10.1016/0531-5565(95)02010-1 · Cited by 104
The Genetic Basis of Peyronie Disease: A Review
Herati, A. S., & Pastuszak, A. W. (2016) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2015.10.002 · Cited by 104
Sakurai, H., Shigemori, N., Hasegawa, K., & Sugita, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8124 · Cited by 101
Coenzyme Q10: Clinical Applications beyond Cardiovascular Diseases
Testai, L., Martelli, A., Flori, L., Cicero, A. F. G., & Colletti, A. (2021) · Nutrients · doi:10.3390/nu13051697 · Cited by 100
Introduction: Oxidation and Inflammation, A Molecular Link Between Non-communicable Diseases
Camps, J., & García‐Heredia, A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-07320-0_1 · Cited by 99
Cavallini, G., Biagiotti, G., Koverech, A., & Vitali, G. (2002) · BJU International · doi:10.1046/j.1464-410x.2002.02738.x · Cited by 98 · cited 1×
“Subsequently, in the early 2000s, carnitine was used to treat PD, specifically for its antioxidant properties, both alone (orally) and together with penile injections of a calcium channel blocker (Verapamil) [94,95].”
BackgroundCarnitine inhibits arachidonic acid turnover, platelet function, and oxidative stress
Pignatelli, P., Lenti, L., Sanguigni, V., Frati, G., Simeoni, I., Gazzaniga, P. P., Pulcinelli, F. M., & Violi, F. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00249.2002 · Cited by 98
Nakamura, T., Matsushima, M., Hayashi, Y., Shibasaki, M., Imaizumi, K., Hashimoto, N., Shimokata, K., Hasegawa, Y., & Kawabe, T. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0338oc · Cited by 94
Davila, H. H., Magee, T. R., Vernet, D., Rajfer, J., & Gonzalez-Cadavid, N. F. (2004) · Biology of Reproduction · doi:10.1095/biolreprod.104.030833 · Cited by 91
Vernet, D., Nolazco, G., Cantini, L., Magee, T. R., Qian, A., Rajfer, J., & Gonzalez-Cadavid, N. F. (2005) · Biology of Reproduction · doi:10.1095/biolreprod.105.041038 · Cited by 88
Treatment of Peyronie's disease with oral pentoxifylline
Brant, W. O., Dean, R. C., & Lue, T. F. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0409 · Cited by 87
Godbout, J. P., Berg, B. M., Krzyszton, C. P., & Johnson, R. W. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.08.003 · Cited by 84
Gene expression in Peyronie's disease
Gonzalez-Cadavid, N. F., Magee, T. R., Ferrini, M., Qian, A., Vernet, D., & Rajfer, J. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900873 · Cited by 84
A NEW CONCEPT IN THE TREATMENT OF PEYRONIEʼS DISEASE
Scott, W. W., & Scardino, P. L. (1948) · Southern Medical Journal · doi:10.1097/00007611-194802000-00017 · Cited by 84 · cited 4×
“f ti i ts in the treat ent of PD dates back over 70 years: specifically, it i t fi t ti i t t e s ccessfully used [89].”
BackgroundMethodInfluentialKim, B.-R., Seo, H.-S., Ku, J.-M., Kim, G.-J., Jeon, C. Y., Park, J. H., Jang, B.-H., Park, S.-J., Shin, Y.-C., & Ko, S.-G. (2013) · Inflammation Research · doi:10.1007/s00011-013-0640-1 · Cited by 82
Sunil, V. R., Vayas, K. N., Cervelli, J. A., Malaviya, R., Hall, L., Massa, C. B., Gow, A. J., Laskin, J. D., & Laskin, D. L. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.05.009 · Cited by 82
Shindel, A. W., Lin, G., Ning, H., Banie, L., Huang, Y.-C., Liu, G., Lin, C.-S., & Lue, T. F. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01790.x · Cited by 81
Antifibrotic activity of galangin, a novel function evaluated in animal liver fibrosis model
Wang, X., Gong, G., Yang, W.-H., Li, Y., Jiang, M., & Li, L. (2013) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2013.04.004 · Cited by 81
Lee, J. G., & Kay, E. P. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-9102 · Cited by 80
Ebrahimpour‐Koujan, S., Gargari, B. P., Mobasseri, M., Valizadeh, H., & Jafarabadi, M. A. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.03.050 · Cited by 79
Role of transforming growth factor beta in the pathophysiology of chronic inflammation.
Wahl, S. M., Costa, G. L., Mizel, D. E., Allen, J. B., Skalerič, U., & Mangan, D. F. (1993) · PubMed · Cited by 78
Role of oxidative stress and antioxidants in Peyronie’s disease
Sikka, S. C., & Hellstrom, W. J. G. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900880 · Cited by 77
Pentoxifylline treatment and penile calcifications in men with Peyronie's disease
Smith, J. F., Shindel, A. W., Huang, Y.-C., Clavijo, R. I., Flechner, L., Breyer, B. N., Eisenberg, M. L., & Lue, T. F. (2011) · Asian Journal of Andrology · doi:10.1038/aja.2010.117 · Cited by 76
Understanding the course of Peyronie's disease
Garaffa, G., Trost, L. W., Serefoglu, E. C., Ralph, D., & Hellstrom, W. J. G. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12129 · Cited by 75 · cited 1×
“The first stage lasts for about 12–18 months [24,25].”
BackgroundAntioxidant Paradox in Male Infertility: ‘A Blind Eye’ on Inflammation
Dutta, S., Sengupta, P., Roychoudhury, S., Chakravarthi, S., Wang, C. W., & Sláma, P. (2022) · Antioxidants · doi:10.3390/antiox11010167 · Cited by 75
Integrins and cadherins as therapeutic targets in fibrosis
Agarwal, S. K. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00131 · Cited by 72
Hartmann, R. M., Fillmann, H. S., Martins, M. I. M., Meurer, L., & Marroni, N. P. (2014) · Phytotherapy Research · doi:10.1002/ptr.5142 · Cited by 71
Levine, L., Rybak, J., Corder, C., & Farrel, M. R. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12334 · Cited by 69 · cited 1×
“The plaque may then evolve towards calcification, which occurs in 20–25% of cases [23].”
BackgroundDel Carlo, M., Cole, A. A., & Levine, L. A. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.01.093 · Cited by 69
Nguyen, H. M. T., Anaissie, J., DeLay, K. J., Yafi, F. A., Sikka, S. C., & Hellstrom, W. J. G. (2017) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2017.08.008 · Cited by 69
Bella, A. J., Lee, J. C., Grober, E. D., Carrier, S., Benard, F., & Brock, G. B. (2018) · Canadian Urological Association Journal · doi:10.5489/cuaj.5255 · Cited by 68
Paulis, G., Brancato, T., D'Ascenzo, R., De Giorgio, G., Nupieri, P., Orsolini, G., & Alvaro, R. (2013) · Andrology · doi:10.1111/j.2047-2927.2012.00007.x · Cited by 67
Self-citationRIEDL, C. R., Sternig, P., Gallè, G., Langmann, F., Vcelar, B. A., Vorauer, K., Wagner, A., Katinger, H. W. D., & Pflüger, H. (2005) · European Urology · doi:10.1016/j.eururo.2005.04.011 · Cited by 66 · cited 2×
“A randomized, double-blind, placebo-controlled study by Riedl (2005) used Superoxide dismutase to treat PD patients.”
MethodKim, E., Kim, M.-S., & Moon, A. (2004) · Cytokine · doi:10.1016/j.cyto.2004.10.001 · Cited by 65
The pathophysiology of Peyronie’s disease
El-Sakka, A. I., Salabas, E., Dinçer, M., & Kadioglu, A. (2013) · Arab Journal of Urology · doi:10.1016/j.aju.2013.06.006 · Cited by 64
Ji, Q., Zhang, L., Jia, H., & Xu, J. (2004) · PubMed · Cited by 64
Beneficial effects of ascorbic acid to treat lung fibrosis induced by paraquat
Rodrigues da Silva, M., Schapochnik, A., Peres Leal, M., Esteves, J., Bichels Hebeda, C., Sandri, S., Pavani, C., Ratto Tempestini Horliana, A. C., Farsky, S. H. P., & Lino-dos-Santos-Franco, A. (2018) · PLOS ONE · doi:10.1371/journal.pone.0205535 · Cited by 64
Safarinejad, M. R. (2010) · International Journal of Impotence Research · doi:10.1038/ijir.2010.20 · Cited by 62
Pathophysiology of Peyronie's disease
Moreland, R. B., & Nehra, A. (2002) · International journal of impotence research · doi:10.1038/sj.ijir.3900875 · Cited by 62
Paulis, G., & Brancato, T. (2012) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152812798889321 · Cited by 60
Self-citationMohamed, H. A., & Said, R. S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107347 · Cited by 60
Freitas, J. P., & Filipe, P. (1995) · Biological Trace Element Research · doi:10.1007/bf02790131 · Cited by 56
Cui, Y., Sun, Y.-W., Lin, H., Su, W.-M., Fang, Y., Zhao, Y., Wei, X., Qin, Y., Kohama, K., & Gao, Y. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2068-5 · Cited by 53
Eltahir, H. M., Fawzy, M. A., Mohamed, E., Al-Rehany, M. A., Shehata, A. M., & Abouzied, M. M. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8353 · Cited by 53
Peyronie’s disease associated with increase in plasminogen activator inhibitor in fibrotic plaque
Davila, H. H., Magee, T. R., Zuniga, F. I., Rajfer, J., & González-Cadavid, N. F. (2005) · Urology · doi:10.1016/j.urology.2005.01.010 · Cited by 52
Huebner, B. R., Moore, E. E., Moore, H. B., Stettler, G. R., Nunns, G. R., Lawson, P. J., Sauaia, A., Kelher, M. R., Banerjee, A. M., & Silliman, C. C. (2017) · Shock · doi:10.1097/shk.0000000000001089 · Cited by 50
WNT2 Locus is Involved in Genetic Susceptibility of Peyronie’s Disease
Dolmans, G. H., Werker, P. M., de Jong, I. J., Nijman, R. J., Study, L. C., Wijmenga, C., & Ophoff, R. A. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02704.x · Cited by 46
Favilla, V., Russo, G. I., Privitera, S., Castelli, T., Madonia, M., La Vignera, S., Condorelli, R., Calogero, A. E., Farina, F. P., Cimino, S., et al. (2014) · Andrologia · doi:10.1111/and.12178 · Cited by 45
Chtourou, Y., Garoui, E. M., Boudawara, T. S., & Zeghal, N. (2012) · Human & Experimental Toxicology · doi:10.1177/0960327112455674 · Cited by 45
Intralesional verapamil for the treatment of Peyronie's disease: a review
Levine, L. A., & Estrada, C. R. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900917 · Cited by 44
(1991) · PubMed · Cited by 44
Paulis, G., Romano, G., Paulis, L., & Barletta, D. (2017) · Advances in Urology · doi:10.1155/2017/4653512 · Cited by 44 · cited 3×
“Instead of being reabsorbed (as occurs in males who are not genetically susceptible to the disease), the hematoma leads to the recruitment of inflammatory cells and proinflammatory cytokines, which inevitably results in the formation of chronic inflammatory tissue that evolves towards fibrosis [20,21].”
BackgroundSelf-citationZhao, W., Wang, L., Yang, J.-L., Li, L., Xu, W., & Li, T. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1613 · Cited by 41
Camps, J. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-07320-0 · Cited by 40
Evaluation of Verapamil Efficacy in Peyronie’S Disease Comparing With Pentoxifylline
Alizadeh, M., Karimi, F., & Fallah, M. R. (2014) · Global Journal of Health Science · doi:10.5539/gjhs.v6n7p23 · Cited by 40
Paulis, G., Cavallini, G., Giorgio, G., Quattrocchi, S., Brancato, T., & Alvaro, R. (2013) · Inflammation & Allergy-Drug Targets · doi:10.2174/1871528112666131205112432 · Cited by 39
Self-citationShiraishi, K., Shimabukuro, T., & Matsuyama, H. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02868.x · Cited by 38
Kubota, Y., Tanaka, N., Kagota, S., Nakamura, K., Kunitomo, M., Shinozuka, K., & Umegaki, K. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.2.0012 · Cited by 38
Segundo, A., & Glina, S. (2020) · Sexual Medicine · doi:10.1016/j.esxm.2019.11.002 · Cited by 38
Lin, S., Chen, R., Chen, Y., Chiang, W., Tsai, T., & Hsieh, B. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.4.811 · Cited by 37
Paulis, G., Barletta, D., Turchi, P., Vitarelli, A., Dachille, G., Fabiani, A., & Romano, G. (2015) · Research and Reports in Urology · doi:10.2147/rru.s97194 · Cited by 37
Self-citationVitamin E Inhibits Proliferation of Human Tenon’s Capsule Fibroblasts in vitro
Haas, A. L., Boscoboinik, D. O., Mojon, D. S., Böhnke, M., & Azzi, A. (2009) · Ophthalmic Research · doi:10.1159/000267899 · Cited by 36
Regulation of interleukin 1 generation in immune‐activated fibroblasts
Huleihel, M., Douvdevani, A., Segal, S., & Apte, R. N. (1990) · European Journal of Immunology · doi:10.1002/eji.1830200404 · Cited by 36
Zhao, H. Y., Li, H. Y., Jin, J., Jin, J. Z., Zhang, L. Y., Xuan, M. Y., Jin, X. M., Jiang, Y., Zheng, H. L., Jin, Y. S., et al. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.413 · Cited by 36
Inhibitory effect of vitamin E (α -tocopherol) on spontaneous platelet aggregation in whole blood
Kakishita, E., Suehiro, A., Oura, Y., & Nagai, K. (1990) · Thrombosis Research · doi:10.1016/0049-3848(90)90233-3 · Cited by 35
HLA Antigens in Peyronie’s Disease
Rompel, R., Mueller-Eckhardt, G., Sehroeder-Printzen, I., & Weidner, W. (1994) · Urologia Internationalis · doi:10.1159/000282566 · Cited by 35
Ya, F., Xu, X., Shi, Y., Gallant, R. C., Song, F., Zuo, X., Zhao, Y., Tian, Z., Zhang, C., Xu, X., et al. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900662 · Cited by 34
Mia, M. M., & Bank, R. A. (2015) · Cell and Tissue Research · doi:10.1007/s00441-015-2285-6 · Cited by 32
Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie's disease
Bivalacqua, T. J., Champion, H. C., & Hellstrom, W. J. G. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900872 · Cited by 31 · cited 3×
“The sources of production of the iNOS enzyme are macrophages, monocytes, T cells, smooth muscle cells, fibroblasts and myofibroblasts [43,45,57].”
BackgroundPourová, J., Applová, L., Macáková, K., Vopršalová, M., Migkos, T., Bentanachs, R., Biedermann, D., Petrásková, L., Tvrdý, V., Hrubša, M., et al. (2019) · Nutrients · doi:10.3390/nu11102286 · Cited by 31
Clinical use of hyaluronic acid in andrology: A review
Zucchi, A., Scroppo, F. I., Capogrosso, P., Salonia, A., Durante, J., Bini, V., Liguori, G., & Bartoletti, R. (2021) · Andrology · doi:10.1111/andr.13083 · Cited by 30
Chu, S., Yang, S., Lue, K., Hsieh, Y., Hsiao, T.-Y., & Lu, K. (2006) · PubMed · Cited by 29
Tang, Y., & Liu, Z. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.5.0007 · Cited by 29
Kruuse, C. R., Jacobsen, T. B., Thomsen, L. L., Hasselbalch, S. G., Frandsen, E., Dige‐Petersen, H., & Olesen, J. (2000) · European Journal of Neurology · doi:10.1046/j.1468-1331.2000.00116.x · Cited by 29
Shockwave Therapy in the Treatment of Peyronie’s Disease
Krieger, J. R., Rizk, P. J., Kohn, T. P., & Pastuszak, A. W. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2019.02.001 · Cited by 28
Upregulation of mRNA expression of MCP-1 by TGF-β1 in fibroblast cells from Peyronie’s disease
Szardening-Kirchner, C., Konrad, L., Hauck, E. W., Haag, S. M., Eickelberg, O., & Weidner, W. (2008) · World Journal of Urology · doi:10.1007/s00345-008-0320-x · Cited by 27
Paulis, G., Barletta, D., Turchi, P., Vitarelli, A., Dachille, G., Fabiani, A., & Gennaro, R. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 27
Self-citationGe, P., Cui, Y., Liu, F., Luan, J. Y., Zhou, X., & Han, J. (2015) · BioScience Trends · doi:10.5582/bst.2015.01000 · Cited by 26
Sochocka, M., Ochnik, M., Sobczyński, M., Gębura, K., Zambrowicz, A., Naporowski, P., & Leszek, J. (2022) · Nutrients · doi:10.3390/nu14102022 · Cited by 26
Peyronie's disease: Review and recent advances
Langston, J. P., & Carson, C. C. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.05.024 · Cited by 25
Lo, H., Wu, M.-W., Pan, S., Peng, C.-Y., Wu, P., & Wu, W. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.03.011 · Cited by 25
Chaturvedi, M., Higuchi, M., & Aggarwal, B. B. (1994) · PubMed · Cited by 25
Doğan, R., Sjostrand, A. P., Yenigün, A., Karataş, E., Koçyiğit, A., & Özturan, O. (2017) · Auris Nasus Larynx · doi:10.1016/j.anl.2017.09.015 · Cited by 25
Paulis, G., D’Ascenzo, R., Nupieri, P., De Giorgio, G., Orsolini, G., Brancato, T., & Alvaro, R. (2012) · International Journal of Andrology · doi:10.1111/j.1365-2605.2011.01219.x · Cited by 24
Self-citationCostantini, T. W., Deree, J., Peterson, C. Y., Putnam, J. G., Woon, T., Loomis, W. H., Bansal, V., & Coimbra, R. S. M. (2009) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923970903183557 · Cited by 24
Evaluation of clinical activity and safety of Daflon 500 mg in type 2 diabetic female patients
Rizk, S. M., & Sabri, N. A. (2009) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2009.08.008 · Cited by 23
Paulis, G., Cavallini, G., Brancato, T., & Alvaro, R. (2013) · Inflammation & Allergy - Drug Targets · doi:10.2174/1871528111312010009 · Cited by 23
Self-citationMental Disorders in Peyronie's Disease: A Swedish Cohort Study of 3.5 Million Men.
Kuja-Halkola, R., Henningsohn, L., D'Onofrio, B., Mills, J., Adolfsson, A., Larsson, H., & Cederlöf, M. (2020) · Journal of Urology · doi:10.1097/ju.0000000000001426 · Cited by 23
Tasanarong, A., Kongkham, S., Duangchana, S., Thitiarchakul, S., & Eiam‐Ong, S. (2011) · PubMed · Cited by 22
Wang, M., Chen, M., Ding, Y., Zhu, Z., Zhang, Y., Wei, P., Wang, J., Qiao, Y., Li, L., Li, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep15357 · Cited by 20
Li, X., Meng, F., Li, H., Hua, X., Wu, L., & Yuan, X. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4283 · Cited by 20
Peyronie’S Disease: A Guide to Clinical Management
Levine, L. A. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-161-1 · Cited by 19
Paulis, G., Paulis, A., Romano, G., Barletta, D., & Fabiani, A. (2017) · Research and Reports in Urology · doi:10.2147/rru.s141748 · Cited by 18
Self-citationGallo, L., & Sarnacchiaro, P. (2019) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2018.08.005 · Cited by 16
Antiplatelet effect of pentoxifylline in human whole blood
Cruz, J. P. D. L., Romero, M. M., Sanchez, P., & de la Cuesta, F. S. (1993) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(93)90218-m · Cited by 15
Peyronie’s disease: A “triple oxygenant therapy”
Ciociola, F., & Colpi, G. M. (2013) · Archivio Italiano di Urologia e Andrologia · doi:10.4081/aiua.2013.1.36 · Cited by 15
Oral therapy for Peyronie’s disease, does it work?
Barrett-Harlow, B., & Wang, R. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.03.24 · Cited by 15
[Clinical evaluation of the use of propoleum in Peyronie's disease].
Lemourt Oliva, M., Filgueiras López, E., Rodríguez Barroso, A., Oramas, E. G., & Ramírez, R. B. (1998) · PubMed · Cited by 15
Gallo, L., & Sarnacchiaro, P. (2019) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2019.03.007 · Cited by 14
Paulis, G., & Giorgio, G. D. (2022) · Antioxidants · doi:10.3390/antiox11091661 · Cited by 11
Self-citation[Propoleum and Peyronie's disease].
Oliva, M. L., Barroso, A. R., Guillen, M., Guerrero, C. V., Cutiño, M. N., & Monzón, A. F. P. (2003) · PubMed · Cited by 10
Paulis, G., & Giorgio, G. D. (2022) · American Journal of Case Reports · doi:10.12659/ajcr.936146 · Cited by 10
Self-citationLow, P., Wang, L., Li, K. D., Shibley, W. P., Cedars, B. E., Holler, J. T., Enriquez, A., Sadeghi‐Nejad, H., Amend, G., & Breyer, B. N. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-022-00589-x · Cited by 10
SCAVENGING ACTIVITY OF DICLOFENAC: INTERACTION WITH ABTS RADICAL CATION AND PEROXYL RADICALS
ROJO, C., Álvarez-Figueroa, M. J., SOTO, M., Cañete, Á., Pessoa-Mahana, C. D., & López‐Alarcón, C. (2009) · Journal of the Chilean Chemical Society · doi:10.4067/s0717-97072009000100014 · Cited by 9
Paulis, G., & Giorgio, G. D. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03614-1 · Cited by 9
Self-citation[Study of propoleum dosage in Peyronie's disease].
Oliva, M. L., Barroso, A. R., Ramírez, R. B., Oramas, E. G., & Castillo, F. M. (2003) · PubMed · Cited by 8
Oliva, M. L., Valdés, R. F., Ramírez, R. B., Santana, J. L., Oramas, E. G., & Merino, A. (2005) · Archivos Españoles de Urología · doi:10.4321/s0004-06142005000900010 · Cited by 8
Efficacy of pentoxifylline in Peyronie’s disease: Clinical case of a young man
Dell’Atti, L., & Ughi, G. (2014) · Archivio Italiano di Urologia e Andrologia · doi:10.4081/aiua.2014.3.237 · Cited by 8
The Incidence, Aetiology, and Presentation of Peyronie's Disease in Sydney, Australia
Johnson, H. M., Weerakoon, P. K., & Stricker, P. D. (2002) · Sexuality and Disability · doi:10.1023/a:1019826310625 · Cited by 7
Wong*, A., Tsang, S. S. L., O, R. Y. M., Chun, S., Tsang, C., Ho, B., Ng, A. T. L., Tsu, J. H., & Lam, W. (2020) · The Journal of Urology · doi:10.1097/ju.0000000000000877.012 · Cited by 7
Huang, C., & Zhang, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-0522-2 · Cited by 7
Peyronie’s Disease in People of African Origin: A Mini Review
Kyei, M. Y., Mensah, J. E., Asante, E., Bray, L. D., & Awuku‐Asabre, J. (2017) · Cited by 5
In vitro effects of L-carnitine on coronary artery bypass grafts.
Güçlü, O., Yüksel, V., Hüseyın, S., Ege, T., Canbaz, S., & Süngün, M. (2013) · Europe PMC (PubMed Central) · Cited by 4
Antioxidative and antiproliferative effects of propolis-reduced silver nanoparticles
Tan, G., llk, S., Zilifdar, F., Foto, E., & Sağlam, N. (2021) · Niğde Üniversitesi Açık Erişim Sistemi · doi:10.12989/anr.2021.10.2.139 · Cited by 4
Non-Surgical Treatment Options for Peyronie s Disease
Çınar, D., Sarı, S., Alkan, H., Ay, K. B., Borcaktepe, E., Duyum, A. Y., Filikçi, S. S., Gençer, E., Senem, Ç., Soylu, S., et al. (2021) · Archives of Current Medical Research · doi:10.47482/acmr.2021.28 · Cited by 3
Research works printed but not linked: 4
- Wein, 2015, Diagnosis and Management of Peyronie Disease, Campbell-Walsh Urology, Volume 1, 722
- Roy, S., Bagchi, D., and Raychaudhuri, S.P. (2013). ROS Mediated Oxidative Stress as a Source of Inflammation. Chronic Inflammation: Molecular Pathophysiology, Nutritional and Therapeutic Interventions, CRC Press.
- Kumar, V., Abbas, A.K., Aster, J.C., and Deyrup, A.T. (2021). Inflammation and Repair. Robbins Essential Pathology, Elsevier Health Sciences. [1st ed.].
- Santana, 2005, Peyronie’s disease. Evaluation of 3 therapeutic modalities: Propoleum, laser and simultaneous propoleum-laser, Arch. Esp. Urol., 58, 931
Cited by
Molecular Mechanisms and Risk Factors Related to the Pathogenesis of Peyronie’s Disease
Mitsui, Y., Yamabe, F., Hori, S., Uetani, M., Kobayashi, H., Nagao, K., & Nakajima, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210133 · Cited by 39
“Several factors, including integrins, thrombospondin 1, ROS, and several proteases (plasmin, cathepsin D, MMP-2, MMP-9), activate latent TGF-β1 by inducing LAP degradation, denaturation, or conformational changes [84,108,109].”
BackgroundChi, J., Bi, W., Lou, K., Ma, J., Wu, J., & Cui, Y. (2024) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeae006 · Cited by 14
Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases
Paulis, G., De Giorgio, G., & Paulis, A. (2024) · Diagnostics · doi:10.3390/diagnostics14111125 · Cited by 11
“In the scientific literature, several articles have appeared in the 21st century that have clarified the important role that “oxidative stress” plays in the pathophysiology of PD [15–22].”
BackgroundSelf-citationUltrasound Elastography as a Diagnostic Tool for Peyronie’s Disease: A State-of-the-Art Review
Paulis, G., Giorgio, G. D., & Paulis, A. (2024) · Diagnostics · doi:10.3390/diagnostics14060665 · Cited by 10
“However, in individuals with a genetic predisposition, the hematoma causes local recruitment of inflammatory cells and pro-inflammatory cytokines, resulting in the formation of chronic inflammatory tissue that subsequently progresses to fibrosis [27–29].”
BackgroundSelf-citationPaulis, G., Paulis, A., Giorgio, G. D., & Quattrocchi, S. (2024) · Metabolites · doi:10.3390/metabo14010055 · Cited by 8
“…is the phase of the disease where surgical intervention is indicated (corporoplasty, plaque incision, and/or implantation of penile prosthesis) [7,19,24 –46 Since OS plays an important role in PD, it is our opinion that, to obtain a more precise evaluation of OS in the disease under…”
BackgroundSelf-citation
Metadata
- Authors
- Paulis, G., De Giorgio, G., & Paulis, L.
- Affiliations
- Peyronie’s Care Center, Department of Urology and Andrology, Castelfidardo Clinical Analysis Center, 00185 Rome, Italy
- Section of Ultrasound Diagnostics, Department of Urology and Andrology, Castelfidardo Clinical Analysis Center, 00185 Rome, Italy
- Corresponding author
- Paulis, Gianni
- ORCID
- Paulis, Gianni
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-12-15
- Volume
- 23
- Issue
- 24
- Pages
- 15969
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9781573
- OpenAlex
- W4311605634
- Cited by
- 21
- References
- 193
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 8 · 2023: 7
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Urology › Urological Disorders and Treatments
- Keywords
- Peyronie's disease, oxidative stress, antioxidant therapy, tunica albuginea, chronic inflammation, erectile dysfunction, penile pain, redox regulation, pathogenesis
- MeSH terms
- Adult, Antioxidants, Chronic Disease, Humans, Erectile Dysfunction, Male, Penile Induration, Penis, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

